Loading...
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Dearnaley, D Syndikus, I Mossop, H Khoo, V Birtle, A Bloomfield, D Graham, J Kirkbride, P Logue, John P Malik, Z
Dearnaley, D
Syndikus, I
Mossop, H
Khoo, V
Birtle, A
Bloomfield, D
Graham, J
Kirkbride, P
Logue, John P
Malik, Z
Citations
Altmetric:
Abstract
Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up.
Authors
Dearnaley, D
Syndikus, I
Mossop, H
Khoo, V
Birtle, A
Bloomfield, D
Graham, J
Kirkbride, P
Logue, John P
Malik, Z
Money-Kyrle, J
O'Sullivan, J
Panades, M
Parker, C
Patterson, H
Scrase, C
Staffurth, J
Stockdale, A
Tremlett, J
Bidmead, M
Mayles, H
Naismith, O
South, C
Gao, A
Cruickshank, C
Hassan, S
Pugh, J
Griffin, C
Hall, E
Syndikus, I
Mossop, H
Khoo, V
Birtle, A
Bloomfield, D
Graham, J
Kirkbride, P
Logue, John P
Malik, Z
Money-Kyrle, J
O'Sullivan, J
Panades, M
Parker, C
Patterson, H
Scrase, C
Staffurth, J
Stockdale, A
Tremlett, J
Bidmead, M
Mayles, H
Naismith, O
South, C
Gao, A
Cruickshank, C
Hassan, S
Pugh, J
Griffin, C
Hall, E
Affiliation
Description
Date
2016
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. 2016, pii: S1470-2045(16) 30102-4 Lancet Oncol